| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3987279 | European Journal of Surgical Oncology (EJSO) | 2008 | 7 Pages |
Abstract
Adding fortnightly IP FU/LV to a standard intravenous regimen is safe, tolerable and provides high peritoneal FU exposure. More reliable peritoneal access is needed to improve the feasibility of this otherwise promising therapeutic approach.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M.T. Seymour, I. Trigonis, P.J. Finan, F. Halstead, R. Dunham, G. Wilson, D. Farrugia, J.D. Chester, J. King, C.B. Brown, M.L. Slevin, S.P. Joel,